| June 27, 2017 |
Webinar: Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells - 55 min.
What will be covered?
- Eliminating donor variability in cytotoxicity assays with single donor-derived primary human KILR CD16 Effector Cells
- Better analysis of antibody’s cytotoxicity profile with better Hill Slopes and higher S:B compared to PBMCs
- Faster assessment of redirected T cell-mediated cytotoxicity with rapid killing kinetics of the CD16 Effector cells
|
Login to view
|
Login to view
|
| March 10, 2017 |
免疫チェックポイント阻害剤の評価に適切なセルベースアッセイ系のご紹介 - 60 min.
What will be covered?
- 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
- PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
- 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系
|
Login to view
|
Login to view
|
| September 9, 2016 |
DiscoverX：常に進化を続けている創薬・新薬開発市場への支援 - 60 min.
What will be covered?
- 2016の創薬市場：「スマート」になった現在の薬剤
- チェックポイント阻害剤の評価系・インターロイキン受容体・GPCR等
- キナーゼ阻害剤・エピジェネティック阻害剤・PPI創薬のスクリーニング
- 候補薬剤の表現型プロファイリング
|
Login to view
|
Login to view
|
| June 29, 2016 |
Webinar: Building Relevant Cell-Based Assays for Co-Stimulatory and Co-Inhibitory Checkpoint Receptors - 60 min.
What will be covered?
- Novel cell-based assays for checkpoint signaling receptors
- Functional assays for biologics and small molecule screening
- Applications for QC lot release testing of biologics
- Assays for CD137, CTLA-4, TIGIT, PD-1, OX-40, CD40, TWEAK, TIM3, and VISTA
- Custom assay development for novel checkpoint targets
|
Login to view
|
Login to view
|
| June 1, 2016 |
Webinar: Specifically Measure Target Cell Death for ADCC, ADCP, BiTe-like Bispecifics, and CAR-T - 45 min.
What will be covered?
- Simple cell-based assays to measure target cell cytotoxicity in a co-culture
- Assays for ADCC, ADCP, bi-specific antibody mediated T-cell redirection, and adoptive T-cell therapies such as CAR-T
- Enabling technology to drive a cancer immunotherapy drug through the discovery and development pipeline
|
Login to view
|
Login to view
|
| March 30, 2016 |
Webinar: Enabling Development of Cancer Immunotherapy Drugs – From Discovery to Combination Strategies - 60 min.
What will be covered?
- Simple cell-based assays for checkpoint signaling receptors
- Assays with human primary cells in co-culture recreating the human tumor microenvironment
- Enabling technologies to move an immune-oncology drug along the discovery and development pipeline
- Drugs targeting PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
|
Login to view
|
Login to view
|
| March 25, 2016 |
免疫チェックポイント阻害剤の評価に適切なセルベースアッセイ系のご紹介 - 60 min.
What will be covered?
- 抗腫瘍免疫応答が増強に活用される免疫チェックポイント阻害剤の評価系
- PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, VISTA などの実施例
- 放射性同位体を使用しないADCC（抗体依存性細胞傷害）の評価系
|
Login to view
|
Login to view
|
| February 17, 2016 |
Biologics Webinar: Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors - 60 min.
What will be covered?
- Novel cell-based assays for checkpoint signaling receptors
- PD-1, PD-L1, PD-L2, TWEAK, CD40, OX40, and VISTA, among others
- Functional assays for biologics and small molecule screening
- Applications for QC lot release testing of biologics
|
Login to view
|
Login to view
|